Genetic analysis indicates that TP63 is required for establishment and preservation of self-renewing progenitors within the basal layer of several epithelial structures, however, the specific contributions of transactivating (TAp63) and dominant-negative (DN-p63) isoforms remain largely undefined. Recent studies have suggested a model in which TA-p63 plays an important role in the establishment of progenitor populations in which expression of DNp63 contributes to the preservation of self-renewing capacity. Our previous studies indicate that DN-p63 is a transcriptional target of p53, however, the absence of overt epithelial deficiencies in p53À/À mice and reports of increased expression of DN-p63 in p53À/À mice suggest p53-independent mechanisms also contribute to expression of DN-p63. Here, we present data indicating that, prolonged loss of p53 leads to the activation of a p53-independent mechanism for transcriptional regulation of DN-p63. This p53-independent mechanism is sensitive to ectopic p53 but not to a p53 mutant that lacks the transactivation domain. We further show that in cells in which p53 is expressed TA-p63-c protein is destabilized in a manner that is p53 dependent and sensitive to pharmacologic inhibition of the 26S proteosome. Consistent with this observation, we demonstrate that loss of p53 leads to the stabilization of TA-p63-c that is reversible by ectopic p53. Finally, we present evidence that disruption of TA-p63-c expression leads to decreased expression of DN-p63 and that overexpression of TA-p63-c was sufficient to enhance the activity of the DN-p63 promoter. Taken together, our studies indicate that TAp63-c is capable of activating expression of DN-p63 and that this mechanism may account for p53-independent expression of DN-p63.
Introduction
Early menarche and late menopause are among the most reliable predictors of breast cancer risk, which together implies a correlation between the overall length of reproductive life and breast cancer risk (Rosner et al., 1994) . During reproductive life the epithelial portion of the mammary gland undergoes periodic and successive regenerative cycles of proliferation and cell death (Smalley and Ashworth, 2003) . The periodicity of these cycles suggests a correlation between the number of regenerative cycles, the length of reproductive life and breast cancer risk. Each cycle begins with mitotic division of a subset of mammary epithelia, known as self-renewing basal progenitors (SRBPs) that possess retained proliferative capacity and are resistant to terminal differentiation. Resulting daughter cells must execute a critical decision to either preserve self-renewing capacity or forfeit self-renewing capacity and initiate a program of terminal differentiation. Preservation of self-renewing capacity confers a prolonged lifespan upon SRBPs, which ensures efficient initiation of subsequent regenerative cycles. The prolonged lifespan may also enable SRBPs to accumulate and harbor mutations for periods of time that are sufficient to initiate breast tumorigenesis. While each cycle represents an opportunity for mutagenesis, genetic lesions occurring in nonself-renewing populations are likely to be neutralized by the protective effects of apoptosis. In contrast, lesions occurring in SRBPs may be harbored from the protective effects of apoptosis and persist through subsequent regenerative cycles. These lesions may deregulate control of self-renewal or be propagated in future regenerative cycles that predispose resulting lineages to carcinogenesis. This implies that mammary SRBPs may represent a site of initiation of breast carcinogenesis, and is consistent with studies indicating that breast cancer initiation is a consequence of unregulated self-renew (Al-Hajj et al., 2003) . Abundant evidence supports the existence of SRBPs in the mammary gland (Chepko and Smith, 1999; Smith and Chepko, 2001; Smalley and Ashworth, 2003) and progress towards their isolation and characterization Dontu et al., 2003; Trosko and Chang, 2003; Welm et al., 2003) has steadily improved our understanding of mammary gland development, cellular stasis and breast cancer initiation.
There is near universal agreement that malignancies result from unregulated clonal expansion of a single cell. In spite of this common ancestor, tumors display obvious cellular heterogeneity in terms of proliferative potential and gene expression patterns. This heterogeneity implies that tumors initiate in cells with retained developmental potency in which a deregulated selfrenewal program gives rise to daughter cells that are incapable of completing a program of differentiation . Studies of breast cancer (Al-Hajj et al., 2003) acute myeloid leukemia (Dick, 1996; Hope et al., 2004) and glioblastoma (Molofsky et al., 2003) provide direct evidence supporting a tumor stem cell model for carcinogenesis. The isolation of breast cancer stem cells demonstrated that they are uniquely tumorigenic and capable of self-renewal. Additionally, recent studies have demonstrated that ectopic expression of oncogenic alleles in SRBPs is sufficient to produce tumors with cellular heterogeneity typical of human breast tumors (Welm et al., 2005) . Currently, no direct evidence exists to indicate that clinical breast cancers initiate in SRBPs, however, the prolonged lifespan and developmental potency of SRBPs coupled to the cellular heterogeneity observed within human breast cancers suggest that breast carcinogenesis results from deregulation of self-renewal in mammary SRBPs. Therefore a greater understanding of genetic programs underlying self-renewal may lead to identification of causative lesions of breast cancer, which will have important implications for prevention and clinical management of breast cancer.
There remains an incomplete understanding of the genetic program underlying the decision to preserve or forfeit self-renewing capacity. Abundant evidence implicates p63, a member of the p53 family of transcription factors in the establishment (Koster et al., 2004) and preservation of epithelial SRBPs (Mills et al., 1999; Yang et al., 1999) . Disruption of TP63 in mice results in profound epithelial hypoplasia and neonatal lethality (Mills et al., 1999; Yang et al., 1999) . This phenotype has been hypothesized to be the result of either the failure to establish adult stem cell pools or a defect in self-renewal that results in a program of nonregenerative differentiation and depletion of the progenitor pool. Several human syndromes, characterized by hypoplasia of various epithelial and apocrine structures have been linked to mutations within the coding region of p63 (Celli et al., 1999; Brunner et al., 2002; van Bokhoven and McKeon, 2002) . Of particular relevance to the maintenance of SRBPs in the mammary gland are truncations of the a-specific carboxy-terminus associated with limb mammary syndrome (OMIN # 603543) (van Bokhoven et al., 2001) . Affected patients exhibit severe to complete hypoplasia of mammary epithelia suggesting that a-isoforms of p63 play a role in either the elaboration or preservation of mammary progenitors. These genetic studies, coupled to reports indicating that DN-p63-a is the predominant isoform of p63 expressed in the basal epithelia of the mammary gland (Nylander et al., 2002) strongly suggest that DNp63-a is required for maintenance of SRBPs.
The gene encoding p63 is capable of producing multiple transactivating (TA-p63) and dominant negative (DN-p63) isoforms (Yang et al., 1998) . This functional diversity results from differential usage of distal (TA specific) and proximal (DN specific) promoters (Yang et al., 1998; Kaelin, 1999) . Three TA isoforms have amino-terminal sequences that are homologous to the transactivation domain of p53. DN-p63 isoforms lack this domain and are capable of acting as dominant-negative regulators of p53 and TAp63. Other studies indicate that DN-p63 isoforms are capable of transcriptional activation (Dohn et al., 2001; Wu et al., 2003) . A second important difference between p53 and p63 is the observed pattern of expression. P53 is widely expressed at low levels and its expression and activity are positively regulated by protein stabilization in response to a variety of cellular signals. In contrast, robust expression of DN-p63 has been identified in the basal layer of epithelial structures (Yang et al., 1998; Parsa et al., 1999; Nylander et al., 2000; Di Como et al., 2002; DiRenzo et al., 2002; Nylander et al., 2002) . The finding that DN-p63 isoforms oppose the activities of p53 and TA-p63, coupled to the observation of a unique pattern of expression that is restricted to the basal layer of epithelial structures suggest that DN-isoforms of p63 preserve SRBPs by modulating transcriptional activation of p53/TA-p63 target genes.
The role of DN-p63 in preservation of SRBPs suggests that loss of DN-p63 expression is a hallmark of forfeiture of self-renewal and initiation of cellular differentiation. In corneal keratinocytes, DN-p63-a has been proposed as a selective marker of limbal epithelia progenitors and that progressive loss of DN-p63-a mRNA expression was correlated with the transition to transient amplification and terminal differentiation (Pellegrini et al., 2001) . Additionally in situ hybridization of skin sections indicate that loss of p63 mRNA is evident during differentiation and that the gradient of mRNA loss is more pronounced than that of p63 protein (Parsa et al., 1999) . This suggests that an important mechanism by which DN-p63 levels decline is through transcriptional repression, and support a model, which holds that activation of the DN-p63 promoter is required for preservation of self-renewal and repression of the DN-p63 promoter mediates forfeiture of self-renewal.
Previously we reported that DN-p63 is a transcriptional target of p53 (Harmes et al., 2003) . This study identified a p53/p63-binding element within the DN-p63 promoter capable of conferring p53-dependent transcriptional activation to a heterologous promoter. Additionally chromatin immune-precipitation indicated that p53 occupies this binding element in asynchronously growing immortalized mammary epithelial cells (IMECs), and that disruption of either the expression or activity of p53 resulted in the loss of DN-p63 expression. This indicated a role for p53 in regulation of DN-p63 expression, which raises important questions regarding differences observed between p53-null mice and p63-null mice. The absence of overt defects in epithelial selfrenewal in the p53-null mouse coupled to reports of TA-p63-c regulates expression of DN-p63 N Li et al increased expression of DN-p63 and TA-p63 in basal epithelia of oral-esophageal structures of p53-null mice (Suliman et al., 2001) indicates that p53-independent mechanisms contribute to expression of DN-p63. In this manuscript we report that, prolonged suppression of p53 expression leads to the activation of p53-independent expression of DN-p63-a. Ectopic expression of p53 under these conditions repressed this mechanism, indicating that the activation of this mechanism was a direct result of p53 ablation. Based on the structural and functional homology between p53 and TA-p63-g we investigated the potential contributions of TA-p63-g to p53-independent expression of DN-p63-a. Our data indicate that while transcriptional regulation of TAp63-g is independent of p53, the stability of TA-p63-g is negatively regulated by p53. Prolonged suppression of p53 stabilizes TA-p63-g and this stabilization is reversed by ectopic expression of p53 into p53-ablated cells. P53-mediated destabilization of TA-p63-g requires the transactivation domain of p53 and is sensitive to pharmacologic inhibition of the 26S proteosome, suggesting a model in which p53 mediates the targeting of TA-p63-g to the 26S proteosome. Finally, we present data indicating that siRNA-mediated suppression of TA-p63-g reduces DN-p63-a expression and that ectopic TA-p63-g is sufficient to activate DN-p63 expression.
These studies suggest a model in which loss of p53 in a mammary SRBP model leads to the stabilization of TA-p63-g, which contributes to the expression of DN-p63-a.
Results
Prolonged ablation of p53 in IMECs leads to activation of p53-independent DN-p63 expression Previously we reported that disruption of p53 expression or activity in IMECs lead to reduced DN-p63 expression. In that report, the p53-ablated IMEC derivative, B3.3, showed reduced levels of DN-p63-a mRNA and no detectable DN-p63-a protein (Harmes et al., 2003) . Continuous passage of the B3.3 derivative lead to reactivation of DN-p63-a expression despite continued shRNA-mediated repression of p53 ( Figure 1a ). This suggested that prolonged suppression of p53 lead to the activation of a p53-independent mechanism sufficient to activate expression of DN-p63. Since our previous studies had reported that disruption of p53 expression or activity resulted in reduced DN-p63 expression, we sought to confirm that expression of DN-p63 was regulated by p53 in IMECs. IMECs were transiently transfected with a p53-directed siRNA or a scrambled control and whole cell lysates were prepared at 0, 24, 48, 72 and 96 h. Western analysis indicated that expression of DN-p63-a was significantly diminished as a result of p53 ablation (Figure 1b ). This result coupled to the observed expression of DN-p63-a in B3.3 suggested that acute suppression of p53 resulted in reduced DN-p63-a expression while prolonged suppression of p53 had resulted in the activation of p53-independent expression of DN-p63.
P53-independent expression of DN-p63 is sensitive to ectopic p53
The previous study indicated that prolonged loss of p53 lead to p53-independent activation of DN-p63. We hypothesized that if activation of this mechanism was the result of p53 loss then that it would be sensitive to ectopic p53. To address this hypothesis, a system was developed to enable expression of various shRNAresistant (SHR) p53 alleles in the p53-ablated B3.3s. Wild-type (wt) p53(SHR) was generated by introducing silent mutations into the six codons targeted by the p53-directed shRNA in B3.3 cells. P53(SHR) mutant alleles were generated by oligo-directed mutagenesis of p53(SHR)-wt ( Figure 2a ). Each p53(SHR) allele was subcloned into pcDNA-3.1(À) and transiently transfected into IMEC and B3.3. Western analysis indicated that while both wt-p53 and p53(SHR) were expressed in IMECs, only p53(SHR) was detectable in B3.3 ( Figure 2b ). This indicated that the SHR allele of p53 was capable of expressing full-length p53 in B3.3s. To TA-p63-c regulates expression of DN-p63 N Li et al confirm that these alleles produced functional p53, wt and transactivation domain deletion mutants of p53(SHR) were co-transfected into B3.3 with a p53-reporter construct containing five copies of the p53/p63-binding element identified in the DN-p63 promoter. Transfectants were removed after 4 h and cells were incubated for 16 h prior to measurement of luciferase activity. Results indicate that p53(SHR) was capable of activating the luciferase reporter while the transactivation domain deletions p53(SHR)-DTA and p53(SHR)-D40 were significantly less active ( Figure 2c ). Western analysis confirmed expression of wt p53 and truncated mutants (Figure 2c lower panel). Finally p53 (SHR) alleles were engineered into the AdEasy XL (Stratagene) adenoviral expression systems and the resulting adenop53(SHR) was shown to be capable of inducing expression of p21 and MDM2 while adeno-p53(SHR)-DTA was not ( Figure 3d ). These results indicate that ectopic expression of the p53(SHR) alleles produces p53 proteins with their expected functional activity.
To determine if the p53-independent mechanism underlying DN-p63 expression in B3.3 is sensitive to p53, B3.3 cells were infected with adenoviruses programmed to express LacZ (control) and p53(SHR)-wt. Cell lysates were prepared at 0, 24, 48, 72 and 96 h postinfection and expression of DN-p63-a was measured by Western analysis. In this analysis we observed a progressive accumulation of DN-p63-a from 0 to 96 h in Cip . Recombinant adenoviruses were generated using the AdEasy XL system (Stratagene). Viruses engineered to express, GFP, LacZ, p53(SHR)-wt and p53(SHR)-DTA were infected into IMECs and harvested at 24 h postinfection. Results indicate that p53(SHR) was able to induce expression of HDM2 and p21
Cip while p53(SHR)-DTA was not. Results in (d) are representative of three separate experiments. 
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N Li et al the adeno-LacZ-infected B3.3. This accumulation was potently suppressed by ectopic expression of p53(SHR)-wt indicating that ectopic p53 was able to actively suppress expression of DN-p63-a in B3.3 (Figure 3a ). To determine if the effects of p53(SHR)-wt were mediated by transcriptional regulation of DN-p63, B3.3 cells were infected with adeno-LacZ and adeno-p53(SHR)-wt and total cellular RNA was isolated at 0, 24, 48, 72 and 96 h. Quantitative PCR was performed to measure the amounts of DN-p63 mRNA relative to the 18S ribosomal subunit. Results indicated that DN-p63 mRNA levels increased steadily through 96 h in LacZinfected B3.3 and that this increase was abolished by ectopic p53(SHR) (Figure 3b ). Ectopic p53 not only blocked the increase observed from 0 to 96 h in the lacZinfected cells but reduced DN-p63 mRNA levels below the baseline represented at T ¼ 0. This result indicates that p53 may actively repress expression of DN-p63 in B3.3. Taken together, these studies indicate that p53-independent expression of DN-p63-a in B3.3 is sensitive to p53, and that p53 may actively suppress expression of DN-p63 in B3.3. These results imply that the activation of this p53-independent mechanism in B3.3 was the result of p53 ablation.
Loss of p53 stabilizes TA-p63-g
The finding that p53-independent expression of DN-p63 is sensitive to ectopic p53 coupled to the previous reports of transcriptional regulation of DN-p63 by multiple members of the p53 family suggested the possibility that additional members of the p53 family might contribute to expression of DN-p63 (Harmes et al., 2003; Waltermann et al., 2003) . Additionally, the reported increase in both DN-p63 and TA-p63 in the basal epithelia of p53-null mouse (Suliman et al., 2001) coupled to the identification of a functional p53/p63 response element in the DN-p63 promoter suggested that TA-p63 isoforms may contribute to p53-independent expression of DN-p63. We therefore sought to determine if TA-p63 isoforms were present and differentially expressed in IMECs and B3.3. Previously we reported that only the DN-p63-a isoform of p63 was recognized by Western analysis of IMECs and B3.3 using the commercially available pan-p63 monoclonal antibody 4A4 (BD Biosciences) (DiRenzo et al., 2002; Harmes et al., 2003) . While this result has been highly reproducible in IMECs and B3.3 it did not rule out the possibility that TA-p63 isoforms were expressed at levels that were below the limits of detection by the 4A4 monoclonal antibody or that post-translational modification of TA-p63 might render it undetectable by 4A4.
To determine if TA-p63 isoforms were differentially expressed in IMECs and B3.3 a 190 bp TA-specific probe (Figure 4a ) was isolated and used to evaluate expression of TA-p63 in IMECs and B3.3 during asynchronous growth or in response to the differentiating agent all-trans retinoic acid (RA). Cells were plated, allowed to attach overnight and refed complete media with 0.01% DMSO (vehicle) or 1 mM all-trans RA.
Whole cell extracts and total cellular RNA were collected at 0, 24, 48, 72 and 96 h post-treatment.
Northern analysis indicated that a single mRNA of approximately 2.8 kb was detected in both IMECs and B3.3. The size of this message is consistent with that of TA-p63-g/p51A (Genbank AB016072), and RT-PCR analysis of these samples indicated that this message is likely to be TA-p63-g (not shown). Northern analysis also indicated that in both IMECs and B3.3, TA-p63-g expression was detectable through 48 h postfeeding before declining and that RA caused a slight decrease in TA-p63-g mRNA levels (Figure 4b ). The identical profile of TA-p63-g expression in IMEC and B3.3 in this study indicates that TA-p63-g mRNA expression is unaffected by p53 status. TA-p63-c regulates expression of DN-p63 N Li et al
Based on the observations that TA-p63-g mRNA was present in both IMECs and B3.3 and that TA-p63-g protein was undetectable with the 4A4 monoclonal antibody, we sought to develop a TA-specific antibody. Peptides corresponding to sequences within the TA domain of TA-p63 (Figure 4a) were synthesized, coupled to KLH and injected into chickens. An affinity-purified IgY fraction was identified that was able to detect ectopic TA-p63-a and TA-p63-g but not DN-p63-a (Figure 4b) . Additionally, data in Figure 6c demonstrate that this TA-specific antibody detects a protein that is depleted by transfection of TA-p63-specific siRNA but not control siRNA. Analysis of TAp63-g protein levels in whole cell extracts collected from IMECs and B3.3 following treatment with DMSO or RA (Figure 4c ) indicated that in IMECs and B3.3 treated with DMSO, TA-p63-g protein persists beyond the point at which its mRNA declines (compare mRNA and protein data at 72 and 96 h in the DMSO-treated samples). This indicates that protein stabilization may play an important role in the regulation of TA-p63-g in both IMECs and B3.3. A second observation from this experiment is that RA caused a decline in TA-p63-g protein levels from 48 to 96 h post-treatment, suggesting that RA is able to destabilize TA-p63-g. Finally, we observed that TA-p63-g protein levels decline more slowly in B3.3 than in IMECs (compare 72 h post-RA between IMECs and B3.3) indicating that RA-mediated destabilization of TA-p63-g is more rapid in IMECs than in B3.3. Taken together, these results indicate that TA-p63-g is destabilized in response to the differentiating agent (RA) and that this destabilization was more rapid in the presence of p53.
P53 actively destabilizes TA-p63-g in a manner that is sensitive to 26S proteosome inhibitors The previous studies indicated that destabilization of TA-p63-g is more rapid in IMEC than in B3.3 which implies that p53 may actively contribute to the destabilization of TA-p63-g in IMECs. To test this, LacZ, wt-p53 and p53-DTA were ectopically expressed in IMECs and whole cell extracts and RNA 0, 24, 48, 72 and 96 h post-infection (Figure 5a ). Northern analysis indicated that TA-p63-g mRNA levels peak at 48 h postinfection and that neither ectopic p53 nor dominant-negative disruption of p53 activity had any significant effect on this pattern. In contrast, ectopic Figure 5 p53 actively destabilizes TA-p63-g in a manner that is dependent on 26S proteosome activity. (a) Disruption of p53 activity indicates that p53 is required for the regulation of TAp63g protein stability. IMECs were infected with adeno-LacZ, adeno-p53(SHR)-wt and adeno-p53(SHR)-DTA. Northern analysis indicates that p53(SHR)-wt and p53(SHR)-DTA have no effect on TA-p63 mRNA. Complementary Western analysis indicates that ectopic p53 reduced levels of TA-p63-g relative to LacZ controls and that p53(SHR)-DTA caused an increase in TA-p63-g levels. (b) Gain of function study suggests that p53 actively destabilizes of TAp63-g. B3.3 were infected with adeno-LacZ, adeno-p53(SHR)-wt and adeno-p53(SHR)-DTA. Northern analysis indicates that p53(SHR)-wt and p53(SHR)-DTA have no effect on TA-p63-g mRNA, while protein analysis indicates that ectopic p53 causes the decline of TA-p63-g protein sharply, suggesting p53 is capable of destabilizing TAp63g. (c) The half-life of TA-p63-g is reduced in the presence of p53. TAp63-g expression plasmid was transfected into IMECs and B3.3. At 20 h post-transfection, cells were treated with 40 mg/ml cycloheximide. Whole cell extracts were harvested at indicated time post-treatment. Western analysis using the 4A4 mAb indicated that ectopic TA-p63-g was more stable in B3.3. (d) Pharmacologic inhibition of the 26S proteosome caused the accumulation of TA-p63-g in IMECs but not in B3.3. IMECs and B3.3 were plated and treated with DMSO (Vehicle) or 10 mM MG-132. Whole cell lysates were prepared at the indicated times and TA-p63-g expression was measured by Western analysis using the TA-specific IgY. Results indicate that pharmacologic inhibition of the 26S proteosome is able to stabilize TA-p63-g in a manner that is p53 dependent. Results in (a-d) are representative of two separate experiments.
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N Li et al expression of p53 in IMECs caused a decline in TA-p63-g protein levels relative to adeno-LacZ-infected samples. Consistent with this, p53-DTA caused the stabilization of TA-p63-g protein levels through 96 h. This result indicated that ectopic p53 was sufficient to destabilize TA-p63-g and that dominant-negative disruption of p53 activity was sufficient to stabilize TA-p63-g. This result is consistent with our finding that TA-p63-g protein is more stable in B3.3 than in IMECs and indicates that the ability of p53 to destabilize TA-p63-g requires the transactivation domain of p53. These studies further suggested that re-expression of wt p53 in B3.3 would cause the destabilization of TA-p63-g. To test this, B3.3s were plated and infected with adeno-lacZ and adenop53(SHR)-wt and adeno-p53(SHR)-DTA. Whole cell extracts and RNA were prepared at 0, 24 48, 72 and 96 h postinfection. Northern analysis indicated that ectopic expression of p53 or p53-DTA caused a slight reduction in TA-p63-g mRNA levels at 48 h a relative to LacZ. Under these conditions, ectopic p53 caused TA-p63-g protein levels to decline sharply, indicating that p53 was sufficient to destabilize TA-p63-g. Together, these studies indicate that p53 is able to destabilize TA-p63-g. The finding that ectopic expression of p53(SHR)-DTA, which is transcriptionally inert disrupted p53-mediated destabilization of TA-p63-g in IMECs indicates that the transactivation domain of p53 was required for destabilization of TA-p63-g. This may suggest that the destabilization of TA-p63-g is mediated by the activation of one or more p53-target genes. The studies described above identify the destabilization of TA-p63-g as a new function of p53. They also suggest that the expression status of p53 is a critical regulator of the half-life of TA-p63-g. To test this, we compared the rate of decay of ectopically expressed TAp63-g in IMECs and B3.3. An expression plasmid encoding TA-p63-g was transiently transfected into IMECs and B3.3s and cells were treated with cycloheximide (CHX) at 20 h post-transfection. Whole cells extracts were prepared at 0. 0.5, 1, 2 and 4 h following CHX treatment and TA-p63-g protein levels were evaluated by Western analysis (Figure 5c ). Results indicate that in IMECs, ectopic TA-p63-g underwent significant decay by 1 h post-CHX treatment. This represented a rate of decay that was comparable to the endogenous p53 (Figure 5c middle panel) . In contrast TA-p63-g was significantly more stable in B3.3 and did not show any significant decay until 4.5 h post-CHX. Interestingly, the decay of p53 in IMECs did not result in the stabilization of TA-p63-g, suggesting that the p53-mediated mechanism underlying destabilization of TAp63-g was established prior to CHX treatment. This finding supports a model in which the p53-dependent destabilization of TA-p63-g is mediated by activation of a p53-target gene that promotes the degradation of TAp63-g.
There is abundant evidence indicating that p53 exerts control over its own stability by activating expression of MDM2, which targets p53 to the 26S proteosome via enzymatic ubiquitination of p53. To determine if the destabilization of TA-p63-g is mediated by the 26S proteosome, IMECs and B3.3s were treated with 0.01% DMSO (vehicle) or the 26S proteosome inhibitor MG-132 (10 mM). Whole cell extracts were prepared at 1, 1.5, 2.5 and 4.5 h post-treatment and TA-p63-g expression was measured by Western analysis. Results indicate that pharmacologic inhibition of the 26S proteosome resulted in increased levels of TA-p63-g in IMECs but had no effect on TA-p63-g levels in B3.3. These results indicate that TA-p63-g is destabilized in a manner that is p53 dependent and sensitive to 26S proteosome inhibition. Taken together these studies support a model in which p53 directs the expression of factor that targets TA-p63-g to the 26S proteosome.
TA-p63-g is capable of activating expression of DN-p63
Our studies indicate that loss of p53 leads to stabilization of TA-p63-g and expression of DN-p63. These findings coupled to our earlier study, which identified DN-p63 as a transcriptional target of p53 in IMECs suggest that TA-p63-g may direct the p53-independent expression of DN-p63. To test this, TA-specific siRNA was used to ablate expression of TA-p63-g in B3.3. Whole cell extracts were prepared at 24, 48, 72 and 96 h post-transfection and Western analysis of TA-p63-g demonstrated that the TA-specific siRNA, but not the scrambled siRNA control was able to mediate reductions of TA-p63-g and DN-p63-a in B3.3 (Figure 6a ). Q-RT-PCR analysis further indicated that the TA-specific siRNA, but not the scrambled siRNA control were able to reduce the levels of DN-p63 mRNA in B3.3 (Figure 6b ). These studies demonstrate that TA-p63-g contributes to transcriptional regulation of DN-p63 in B3.3. This result coupled to studies indicating that TAp63-g is destabilized in IMECs as well as in B3.3 suggested that TA-p63-g might also contribute to expression of DN-p63 in IMECs. Transient transfection of a TA-specific siRNA but not a control siRNA resulted in decreased expression of DN-p63 in IMECs suggesting that TA-p63-g may also contribute to expression of DN-p63 in IMECs. This result coupled to the data indicating that transient ablation of p53 results in decreased expression of DN-p63 in IMECs suggests that in IMECs both p53 and TA-p63-g contribute to the transactivation of the DN-p63 promoter (see Discussion).
The finding that TA-p63 ablation caused a reduction in DN-p63 mRNA suggested that TA-p63-g may be sufficient to induce DN-p63 expression. TA-p63-g was transiently transfected into the human lung adenocarcinoma H1299, which was chosen because it lacks p53 and does not express detectable levels of DN-p63. Western analysis confirmed the ectopic expression of TA-p63-g in H1299 (Figure 6d) . At 24 h post-transfection, total cellular RNA was harvested and Q-PCR was used to measure DN-p63 mRNA relative to the 18S ribosomal subunit. Results indicate that ectopic expression of TAp63-g in H1299 cells caused a sevenfold increase in DNp63 mRNA (Figure 6d ). Western analysis confirmed ectopic expression of TA-p63-g. These results coupled to the loss of function studies described above indicate that TA-p63-c regulates expression of DN-p63 N Li et al TA-p63-g is capable of activating expression of DN-p63. These findings support a model in which loss of p53 leads to the stabilization of TA-p63-g, which drives expression of DN-p63.
Discussion
Previously we reported that disruption of either the expression or activity of p53 resulted in reduced expression of DN-p63. While this study indicated a functional relationship between p53 and DN-p63 expression it also raised important questions regarding the lack of overt epithelial deficiency and increased expression of both DN-p63 and TA-p63 in p53-null. Here we report that prolonged ablation of p53 expression leads to increased activity of a p53-independent mechanism that promotes expression of DN-p63. We also present data indicating that this mechanism is sensitive to ectopic p53. Our data support a mechanistic model in which loss of p53 leads to the stabilization of TA-p63 isoforms that contribute to expression of DN-p63. Additionally we present data indicating that disruption of p53 activity in IMECs leads to stabilization of TA-p63-g and that re-expression of p53 in the p53-ablated B3.3 destabilizes TA-p63-g.
Our studies indicate that the ability of p53 to destabilize TA-p63-g requires the transactivation domain of p53 and is sensitive to pharmacologic inhibition of the 26S proteosome. These results suggest that the mechanism by which p53 destabilizes TA-p63-g is through the activation of a target gene that directs TA-p63-g to the 26S proteosome. This model is consistent with one proposed in a recent study in which TA-p63 expression was controlled by its DNA binding and transactivation activities and is degraded via the 26S proteosome (Ying et al., 2005) . That study also presented interesting and compelling data to indicate that the degradation of TA-p63 is independent of mdm2. Our data indicate that loss of p53 triggers an adaptive response that preserves expression of p63 isoforms. We propose that this adaptive response accounts for the lack of overt epithelial deficiencies in the p53-null mouse.
In this study, we describe the identification of a p53-independent mechanism that may underlie the ability of B3.3 cells to express DN-p63. We later present data that this mechanism is also active in IMECs, which express wt-p53. This finding suggests that TA-p63-g plays a positive role in the regulation of DN-p63 regardless of p53 status. It also suggests that prolonged loss of p53 in B3.3 lead to selective pressure upon the cells to stabilize TA-p63-c regulates expression of DN-p63 N Li et al TA-p63-g thereby enhancing it's ability to transactivate target genes. These studies suggest that there is redundancy in transcriptional regulation of DN-p63.
We also note in this study that expression of both DNp63 and TA-p63-g is induced by growth factor stimulation of the IMEC and B3.3 cells. This is apparent in the northern and western blots in which expression of p63 isoforms persists for 48 h following growth factor stimulation. Data presented in Figure 5a indicates that ectopic wt-p53 has a suppressive effect on DN-p63 in IMECs and we believe that this effect may be due to the ability of p53 to oppose mitogenic stimulation. Our earlier study indicating that disruption of the expression or activity of p53 lead to decreased expression of DNp63 suggested a positive role for p53 in transcriptional regulation of DN-p63. In that report we proposed a model in which positive regulation of DN-p63 by p53 may underlie the preservation of basal epithelia during mammary gland involution (Harmes et al., 2003) . During involution p53 contributes to apoptosis in luminal epithelia of the mammary gland (Jerry et al., 1999 (Jerry et al., , 2000 and we proposed that p53 might also activate expression of DN-p63 in basal epithelia thereby protecting them from apoptosis. While this model remains untested, we believe that the bidirectional effect of p53 on DN-p63 expression is consistent with a role in preserving cellular stasis throughout the mammary regenerative cycle. Specifically this model would suggest that during the initial proliferative phase of the regenerative cycle mitogenic stimulation directs the expansion of a progenitor population and this expansion would be sensitive to activation of p53. During this stage activation of p53 would block mitogenic signaling, which would have the effect of arresting proliferation and downregulating mitogen-induced expression of p63 isoforms. At the terminal phases of the regenerative cycle activation of p53 contributes to the apoptotic involution of the mammary gland. In order to preserve the resistance to apoptosis characteristic of SRBPs, activation of p53 in basal epithelia may direct the expression of DN-p63 which has been reported to block p53-induced apoptosis. Work presented in this manuscript indicates that p53 has only subtle effects on TA-p63-g mRNA levels but is able to mediate the proteolytic destabilization of TAp63. These studies also indicate that p53-mediated destabilization of TA-p63-g requires the transactivation domain of p53. Two models have been previously proposed to account for the destabilization of p63 isoforms. Ratovitski et al. (2001) demonstrated that p53 and two isoforms of DN-p63 (p40 and DN-p63-a) were able to physically interact through residues within the DNA-binding domains of p53 and DN-p63. They further demonstrate that this interaction is sufficient to degrade DN-p63 isoforms in a manner that is sensitive to caspase 1 inhibition and resistant to either 26S proteosome inhibition or calpain inhibition. They also note that inhibition of 26S did result in overall stabilization of p63 isoforms suggesting that the stability of p63 is regulated by the 26S proteosome and by caspase inhibition. Their study supports a 'tethering' model in which the interaction of p53 and DN-p63 mediates the activation of caspase 1-dependent degradtion of DNp63. Since the DNA-binding domain of p63 is common among all known isoforms, it is reasonable to predict that similar intractions occur between p53 and TA-p63 and that these interactions might mediate a p53-dependent and caspase-mediated degradation of TAp63 isoforms. A second model, proposed by Ying et al. (2005) , suggested that the stability of TA-p63 is governed by a feedback loop in which activation of a p53 or p63 target gene feeds back to destabilize TA-p63. They note that mutants associated with ectrodactyly ectodermal dysplasia and facial clefting are unable to bind DNA, are transcriptionally inert and are highly stable. The authors demonstrate that mutated versions of TA-p63-g are more stable than wt TA-p63-g and that the transactivation domain of TA-p63-g is required for destabilization. Their studies are consistent with a feedback loop model in which either TA-p63 or p53 directs the expression of a factor that mediates TA-p63-g degradation. The present study indicates that p53 plays a role in the 26S-mediated degradation of TA-p63-g and does so in a manner that is dependent upon the transactivation domain of p53. Since this domain is also known to be important for interaction of MDM2 (Kussie et al., 1996) , our study cannot discern between the 'tethering' and the 'feedback loop.' However, these models are not mutually exclusive and in fact may be interdependent as is the case with the ability of p53 to direct expression of MDM2 which then destabilizes p53.
There is a growing body of evidence that within breast tumors as well as other malignancies, there exists a small fraction of cells that are uniquely tumorigenic and uniquely able to self-renew. These studies have suggested that cancer initiation is a consequence of unregulated self-renewal and have focused attention on the genetic pathways underlying self-renewal. Murine (Mills et al., 1999; Yang et al., 1999; Koster et al., 2002) and human (Celli et al., 1999; Brunner et al., 2002; van Bokhoven and McKeon, 2002) genetic analyses have clearly implicated p63 in the establishment and preservation of self-renewing populations within multiple epithelial structures. Additional studies have indicated that DN-p63 isoforms predominate in the basal epithelia of the mammary gland and other epithelial structures (Nylander et al., 2002) . This suggests the deregulation of DN-p63 expression may be a feature of unregulated selfrenewal and possibly cancer initiation. Our findings indicate that regulation of DN-p63 expression is altered in response to loss of p53. Since p53 signaling is disrupted in the majority of human malignancies, our study identifies a mechanism by which loss of p53 might lead to uncontrolled or poorly controlled self-renewal.
Materials and methods

Cell lines
Establishment of the IMEC line has been previously described (DiRenzo et al., 2002) . IMECs are cultured in DMEM/F12 supplemented with 10 ng/ml cholera toxin, 5 mg/ml insulin, TA-p63-c regulates expression of DN-p63 N Li et al 10 ng/ml EGF, 0.5 mg/ml hydrocortisone, 10 mM Hepes-KOH (pH ¼ 7.3), 50 mg/ml BSA, Penn/Strep, L-glutamine and 50 mg/ ml puromycin. The p53-ablated IMEC derivative, B3.3 was established previously (Harmes et al., 2003) . B3.3 are cultured in IMEC growth media supplemented with 50 mg/ml G418. The non-small-cell lung cancer cell line, H1299 (ATCC# CRL-5803) was cultured in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum, L-glutamine and Penn/Strep.
Plasmids
The p53(SHR) family was generated by mutagenizing the segment of the p53 coding region indicated in Figure 3a . The sequence of the mutagenesis oligo used to introduce silent mutations is: 5 0 -CCA TCA TCA CAC TGG AAG ATT CAA GCG GCA ACC TTC TGG GAC GGA ACA GCT TTG AGG-3. Generation of p53(SHR) was carried out using a modification of the p-Alter Mutagenesis system (Promega). Generation of p53(SHR)-DTA and p53(SHR)-D40 was carried out by oligo-directed mutatgenesis using the p-Alter system. All mutagenized fragments were confirmed by sequence analysis. Wt p53 and the p53(SHR) alleles were sublconed into pcDNA3.1(À) as well as into the adenoviral shuttle vector, pShuttle-CMV (Stratagene) by standard cloning procedures. The reporter plasmid, (p53RE) 5 -tk-luciferase consists of five copies of the p53/p63-binding element identified in the DN-p63 promoter fused to the minimal thymidine kinase promoter from HSV and firefly luciferase.
Real-time PCR
Quantitative PCR was performed by reverse transcription of total cellular RNA. Total cellular RNA was isolated using the RNeasy system (Qiagen), according to the manufacturer's instructions. First-strand cDNA was prepared using the Superscript First Strand cDNA synthesis system (Invitrogen). All cDNAs were analysed by PCR to determine the quality of the preparation. For quantitative PCR, genes were amplified in the presence of SYBR-green and incorporated fluorescence was measured and normalized to amplification of the 18S ribosomal subunit. Amplification of DN-p63 isoforms was achieved using the following primers: forward 5 0 -ATGTTG-TACCTGGAAAAC-3 0 and reserves 5 0 -ATGGGGCATG TCTTTGC-3 0 . Amplification of the 18S ribosomal subunit was achieved using the following primers: forward 5 0 -GTA ACCCGTTGAACCCCATT-3 0 and reverse 5 0 -CCATCC AATCGGTAGTAGCG-3 0 . Amplification of b-actin was achieved using the following primers: forward 5 0 -GCG GGAAATCGTGCGTGACA-3 0 and reverse 5 0 -AAGGAA GGCTGGAAGAGTGC-3 0 Western analysis Western analysis was performed as previously described. DNp63 was detected using the pan-p63 monoclonal antibody 4A4 (Oncogene Research). Antibodies directed against p53 (Santa Cruz Biotech FL393) and b-actin (Santa Cruz C-11) were used in all Western analyses. TA-p63 was detected using a TAspecific chicken IgY developed in this laboratory. All primary antibodies were detected via immunoglogulin-linked horseradish peroxidase and ECL-plus (Amersham).
Northern analysis
Total RNA was prepared using RNeasy system (Qiagen). Of total cellular RNA, 20 mg was resolved in a 1% agarose denaturing gel. Northern hybridizations were performed as previously described (Harmes et al., 2003) . TA-p63 was detected by probing blots with a 207 bp EcoRI/MscI fragment representing the TA-domain of TA-p63.
Adenoviral generation
Replication defective, recombinant adenoviruses programmed to express the various p53(SHR) alleles were generated using the AdEasy XL (Stratagene) adenoviral expression system. Viral titers were generated by amplifaction in 293-AD cells per manufacturer's protocol. Viral titers were determined by serial dilution and quantitative analysis of recombinant products. Cells were infected at a multiplicity of infection of 5 or greater to achieve B100% gene transmission.
Transfection
For reporter assays, IMEC-B3.3 cells were plated at 50 000 per well in 24-well cluster dishes. On the following day, the cells were transfected with 200 ng of DNA including 50 ng of reporter plasmid, 100 ng of expression plasmid, and 50 ng of CMV-b-galactosidase-expression plasmid using Polyfect (Qiagen). After 20 h post-transfection, luciferase assay were performed as previously described. Data were shown as the fold induction following normalization by b-galactosidase activity and error bars represents s.d. from triplicate transfection with similar results observed in at least two independent experiments. For siRNA studies, IMECs and IMECs-B3.3 were plated at 250 000 cells per well in six-well cluster dishes. In all, 50 pmol TA-p63-directed siRNA duplexes and 50 pmol gspecific tail siRNA duplexes (Invitrogen) were transfected using Lipofectamine reagent (Invitrogen) and OptiMem cell culture media (Invitorgen), according to the manufacturer's instructions. The scrambled siRNA duplex serves as the siRNA transfection-negative control. The siRNA sequence used to target the g-specific tail was UGCUGGUCAUGUAAUAAUAdTdT. The SiRNA sequence used to target TA-specific isoforms of p63 was GCCUAUAUGUUCA-GUUCAGCCCAUU.
For the transient transfection of H1299 cells, cells were plated at 90% confluence per six-well plate. In all 1 mg of Tap63g expression plasmid or pCDNA3.1 empty vector was transfected with Lipofectamine reagent (Invitrogen) as instructed by manufacturer.
